Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations

Kun Yu, Chee How Lee, Puay Hoon Tan and Patrick Tan
Kun Yu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chee How Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Puay Hoon Tan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Tan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-04-0085 Published August 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Identification of molecular subtypes of breast cancer by unsupervised analysis. A, unsupervised hierarchical clustering of 98 invasive breast tumors using the top 376 genes exhibiting the highest variation in gene expression. B, gene clusters and examples of their members: ER+/Luminal epithelial cluster (ERSR1, GATA3, TFF1, TFF3, STC2), ERBB2 cluster (ERBB2, maspin, SFRP1), Normal east/adipose-enriched cluster (FBP4, ADH1B), immune cluster (IGLJ3, IGHM, IGLα). A complete list of the 376-gene set and the gene clusters are available for download4 (see Materials and Methods). C, principal component (Comp. 1, 2, and 3) analysis using the 376-gene set. Similar molecular groupings are observed as in A.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Kolmogorov-Smirnov (KS) analysis to determine whether genes exhibiting strong differences in expression between the ER+ and ER− subtypes in our Asian data set also exhibited a similar behavior in the Caucasian data set. The X axis represents the list of genes from the Caucasian data set (10) ordered by their signal to noise ratio (20) according to their ER classification. The running sum (Y axis) of consecutive values of the Vector V (see ref. 18 for details) indicates the distribution of gene expression signatures derived from the Asian-Chinese population within the Caucasian data set, after removal of several well-known ER marker genes (i.e., ESR1, GATA3, TFF1, TFF3, XBP1, MYB, IGFR1, MUC1, BCL2). The statistic S (KS score) is the maximum score of the running sum. The statistical significance of statistic S is indicated by the P-value (see Supplementary Information4 and ref. ,18 for details).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    A–D, examples of DCIS samples used in this study. Two samples are shown (A, B), and (C, D). The DCIS status of each sample was confirmed both by examination of paraffin-embedded H&E sections of samples (A and C, HE) and by examination of frozen cryosections (B and D, FS) of the actual sample that was processed for expression profiling. DCIS samples express the hallmark genes of invasive carcinoma subtypes. E, PCA analysis of normal tissue and DCIS tumors on the 367-gene set. Red, normal samples; blue, DCIS samples. The vertical axis, principal component 1; the horizontal axis, principal component 2. F, unsupervised clustering of DCIS and IDC tumors. Lines, DCIS samples. Eight of 17 DCIS samples cluster within the ERBB2+ group, 8 samples in the ER+ group, and 1 sample was in the ER− group. Red, ER+/Luminal-like; pink, ERBB2+; blue, ER−/Basal-like. Colored bars to the right of the clustergram: A, Luminal epithelial genes with ER; B, genes with ERBB2; C, Basal epithelial genes.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    A, summary of subtype-specific and commonly regulated genes for the ER+ and ERBB2+ molecular subtypes. U, up-regulated genes; D, down-regulated genes. For example, there are 113 genes up-regulated and 310 genes down-regulated during the normal→DCIS (ER+) transition. Numbers in bold, overlapping genes between the subtypes. (Inv, invasive; N/A, not available. B, a comparison of genes regulated during the normal/DCIS transition between our study and the study of Ma et al., (15) . Numbers outside the intersecting areas, genes that were found to not overlap between the studies; numbers in the joint areas, overlapping genes commonly identified in the both studies.

Tables

  • Figures
  • Additional Files
  • Table 1

    Overlapping genes between this study and the study by Ma et al. compared with overlaps obtained by random permutation

    ER+Common genesERBB2+
    Down-regulated in normal/DCIS transition
     Random gene-set size150*150150
     No. of overlapping genes (99.9%)11 (13†)11 (13)11 (13)
     Actual experiment324717
    Up-regulated in normal/DCIS transition
     Random gene-set size7935110
     No. of overlapping genes (99.9%)9 (11)6 (7)11 (13)
     Actual experiment17923
    • NOTE. See Results section (ref. 15 ; Ma et al.).

    • * For genes down-regulated in the normal/DCIS transition, all three types of samples (ER+, ERBB2+, and common genes) contained a similar number of genes (164, 149 and 150). Thus, a random-set size of 150 genes was used in all three types of samples.

    • † Numbers within parentheses indicate the maximum number of overlapping genes observed across 10,000 random sets.

  • Table 2

    Genes that were commonly regulated for both ER+ and ERBB2+ molecular subtypes in the normal/DCIS transition

    Probe_IDGene nameGene symbolUniGene
    Down
     204294_ataminomethyltransferase(glycine cleavage system protein T) AMT Hs.12
     201012_at annexin A1 ANXA1 Hs.78225
     203324_s_at caveolin 2 CAV2 Hs.139851
     200985_s_atCD59 antigen p18–20(antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) CD59 Hs.278573
     221556_atCDC14 cell division cycle 14 homolog B(Saccharomyces cerevisiae) CDC14B Hs.22116
     202259_s_at hypothetical protein from BCRA2 region CG005 Hs.23518
     203477_at collagen, type XV, α1 COL15A1 Hs.83164
     201289_at cysteine-rich, angiogenic inducer, 61 CYR61 Hs.8867
     201581_at hypothetical protein DJ971N18.2 DJ971N18.2 Hs.169358
     207761_s_at DKFZP586A0522 protein DKFZP586A0522 Hs.288771
     203881_s_atdystrophin(muscular dystrophy, Duchenne and Becker types) DMD Hs.169470
     212730_at desmuslin DMN Hs.10587
     208370_s_at Down syndrome critical region gene 1 DSCR1 Hs.184222
     201540_at four and a half LIM domains 1 FHL1 Hs.239069
     218804_at hypothetical protein FLJ10261 FLJ10261 Hs.26176
     218823_s_at hypothetical protein FLJ20038 FLJ20038 Hs.72071
     203706_s_atfrizzled homolog 7(Drosophila) FZD7 Hs.173859
     209292_at inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 Hs.34853
     208966_x_at interferon, gamma-inducible protein 16 IFI16 Hs.155530
     204773_atinterleukin 11 receptor,α IL11RA Hs.64310
     206766_atintegrin,α10 ITGA10 Hs.158237
     201656_atintegrin,α6 ITGA6 Hs.227730
     201466_s_atv-jun sarcoma virus 17 oncogene homologue(avian) JUN Hs.78465
     209351_atkeratin 14(epidermolysis bullosa simplex, Dowling-Meara, Koebner) KRT14 Hs.355214
     202350_s_at matrilin 2 MATN2 Hs.19368
     209583_s_at antigen identified by monoclonal antibody MRC OX-2 MOX2 Hs.79015
     202431_s_atv-myc myelocytomatosis viral oncogene homolog(avian) MYC Hs.79070
     209272_atNGFI-A binding protein 1(EGR1 binding protein 1) NAB1 Hs.107474
     209289_at nuclear factor I/B NFIB Hs.33287
     211671_s_atnuclear receptor subfamily 3, group C, member 1(glucocorticoid receptor) NR3C1 Hs.75772
     218589_at purinergic receptor P2Y, G-protein coupled, 5 P2RY5 Hs.123464
     203131_at platelet-derived growth factor receptor, α polypeptide PDGFRA Hs.74615
     203097_s_atPDZ domain containing guanine nucleotide exchange factor(GEF)1 PDZGEF1 Hs.373588
     218319_atpellino homolog 1(Drosophila) PELI1 Hs.7886
     207943_x_at pleiomorphic adenoma gene-like 1 PLAGL1 Hs.75825
     201578_at podocalyxin-like PODXL Hs.16426
     209147_s_at phosphatidic acid phosphatase type 2A PPAP2A Hs.406043
     215707_s_atprion protein(p27–30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) PRNP Hs.74621
     221523_s_at Ras-related GTP binding D RRAGD Hs.238679
     200937_s_at ribosomal protein L5 RPL5 Hs.180946
     202037_s_at secreted frizzled-related protein 1 SFRP1 Hs.7306
     200795_atSPARC-like 1(mast9, hevin) SPARCL1 Hs.75445
     204955_at sushi-repeat-containing protein, X-linked SRPX Hs.15154
     216037_x_attranscription factor 7-like 2(T-cell specific, HMG-box) TCF7L2 Hs.348412
     208944_attransforming growth factor,β receptor II(70/80 kDa) TGFBR2 Hs.82028
     204731_attransforming growth factor,β receptor III(betaglycan, 300 kDa) TGFBR3 Hs.342874
     213900_at Friedreich ataxia region gene X123 X123 Hs.77889
    UP
     204170_s_at CDC28 protein kinase regulatory subunit 2 CKS2 Hs.83758
     212057_at KIAA0182 protein KIAA0182 Hs.75909
     210519_s_atNAD(P)H dehydrogenase, quinone 1 NQO1 Hs.406515
     208874_x_atprotein phosphatase 2A, regulatory subunit B′ (PR 53) PPP2R4 Hs.400740
     208734_x_at RAB2, member RAS oncogene family RAB2 Hs.78305
     200832_s_atstearoyl-CoA desaturase(δ-9-desaturase) SCD Hs.119597
     209218_at squalene epoxidase SQLE Hs.71465
     201689_s_at tumor protein D52 TPD52 Hs.2384
     36936_at tissue specific transplantation antigen P35B TSTA3 Hs.404119
    • NOTE. See Fig. 4B<$REFLINK> . “Down” indicates down-regulation in the normal/DCIS transition.

    • Abbreviation: ID, identification.

Additional Files

  • Figures
  • Tables
  • Supplementary Data, Yu et al.

    Files in this Data Supplement:

    • Fig 1 Complete Data Table
    • Fig 1 Gene Tree File
    • Fig 1 Array Tree File
    • Fig 2F Complete Data Table
    • Fig 2F Gene Tree File
    • Fig 2F Array Tree File
    • Full gene list for Fig 3A
    • Full gene list for Fig 3B
PreviousNext
Back to top
Clinical Cancer Research: 10 (16)
August 2004
Volume 10, Issue 16
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations
Kun Yu, Chee How Lee, Puay Hoon Tan and Patrick Tan
Clin Cancer Res August 15 2004 (10) (16) 5508-5517; DOI: 10.1158/1078-0432.CCR-04-0085

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations
Kun Yu, Chee How Lee, Puay Hoon Tan and Patrick Tan
Clin Cancer Res August 15 2004 (10) (16) 5508-5517; DOI: 10.1158/1078-0432.CCR-04-0085
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1α, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma
  • Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor α in Human Breast Carcinoma
  • Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Show more Regular Articles

Molecular Oncology, Markers, Clinical Correlates

  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
  • Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma
  • OCT4
Show more Molecular Oncology, Markers, Clinical Correlates
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement